GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » 10x Genomics Inc (NAS:TXG) » Definitions » Other Current Assets

10x Genomics (10x Genomics) Other Current Assets : $20.8 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is 10x Genomics Other Current Assets?

10x Genomics's other current assets for the quarter that ended in Mar. 2024 was $20.8 Mil.

10x Genomics's quarterly other current assets declined from Sep. 2023 ($20.7 Mil) to Dec. 2023 ($18.8 Mil) but then increased from Dec. 2023 ($18.8 Mil) to Mar. 2024 ($20.8Mil).

10x Genomics's annual other current assets increased from Dec. 2021 ($14.9 Mil) to Dec. 2022 ($19.2 Mil) declined from Dec. 2022 ($19.2 Mil) to Dec. 2023 ($18.8 Mil).


10x Genomics Other Current Assets Historical Data

The historical data trend for 10x Genomics's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

10x Genomics Other Current Assets Chart

10x Genomics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Assets
Get a 7-Day Free Trial 8.03 29.60 14.92 19.21 18.79

10x Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.36 20.18 20.68 18.79 20.79

10x Genomics Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


10x Genomics Other Current Assets Related Terms

Thank you for viewing the detailed overview of 10x Genomics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


10x Genomics (10x Genomics) Business Description

Traded in Other Exchanges
Address
6230 Stoneridge Mall Road, Pleasanton, CA, USA, 94588
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Executives
Serge Saxonov director, 10 percent owner, officer: Chief Executive Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
James Wilbur officer: Chief Commercial Officer C/O 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588-3260
Benjamin J. Hindson director, officer: See Remarks 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Justin J. Mcanear officer: Chief Financial Officer 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
John R Stuelpnagel director 10X GENOMICS, INC., 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94588
Mathai Mammen director THERAVANCE,INC., 901 GATEWAY BLVD., SOUTH SAN FRANCISCO CA 94080
Bradford Crutchfield officer: Chief Commercial Officer 6230 STONERIDGE MALL ROAD, PLEASANTON CA 94547
Sridhar Kosaraju director 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Bryan E Roberts director C/O VENROCK ASSOCIATES, 2494 SAND HILL ROAD STE 200, MENLO PARK CA 94025
Venrock Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Associates Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Vi, L.p. 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Venrock Partners Management Vi, Llc 10 percent owner 3340 HILLVIEW AVENUE, PALO ALTO CA 94304
Foresite Capital Fund I, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Paladin Capital Management, Llc 10 percent owner 2020 K STREET, NW, SUITE 620, WASHINGTON DC 20006